Aleksandra Kułakowska | Medicine and Health Sciences | Innovative Research Award

Published on by Innovation Technologist

Innovative Research Award

Aleksandra Kułakowska
University of Opole

Aleksandra Kułakowska
Affiliation University of Opole
Country Poland
Documents 9
Subject Area Medicine and Health Sciences
Event Global Innovation Technologist Awards
ORCID 0000-0001-5466-7167

Aleksandra Kułakowska is a researcher affiliated with the University of Opole whose scholarly work contributes to contemporary discussions in medicine, public health, patient care, and clinical practice. Her publications explore diverse healthcare topics including nephrology, cardiology, dermatology, women’s health, infection prevention, and quality-of-life assessment. Through peer-reviewed academic articles, she has participated in the dissemination of evidence-based medical knowledge and interdisciplinary healthcare perspectives.[1]

Abstract

This article presents an overview of the academic profile and scholarly contributions of Aleksandra Kułakowska. Her published work addresses clinically relevant healthcare challenges, emphasizing patient well-being, disease management, preventive medicine, and evidence-based healthcare practices. The breadth of topics represented within her publication portfolio demonstrates engagement with multidisciplinary medical research and healthcare education.[2]

Keywords

Medicine, Health Sciences, Clinical Research, Patient Care, Public Health, Dialysis, Medical Education, Healthcare Quality.

Introduction

Healthcare research plays an important role in improving patient outcomes and informing clinical decision-making. Aleksandra Kułakowska’s academic contributions align with this objective by addressing issues related to chronic disease management, healthcare quality, and patient-centered care. Her work contributes to broader efforts aimed at enhancing understanding of medical conditions and treatment outcomes.[3]

Research Profile

The research interests of Aleksandra Kułakowska encompass several areas of medicine and health sciences. Her publications address dialysis and quality of life, mental health implications of chronic treatment, surgical site infection prevention, women’s health, cardiovascular disorders such as Brugada syndrome, and rare dermatological conditions including Schnitzler syndrome. These studies demonstrate interdisciplinary engagement with contemporary healthcare topics.[4]

Research Contributions

  • Evaluation of quality-of-life outcomes among dialysis patients.
  • Assessment of mental health considerations associated with chronic renal therapy.
  • Review of updated guidelines concerning surgical site infections.
  • Analysis of healthy lifestyle interventions for patients experiencing PMS symptoms.
  • Compilation of clinically relevant information regarding Brugada syndrome.

Publications

  • Schnitzler syndrome – a rare cause of chronic urticaria. Case report (2025).
  • What impact does dialysis have on the patient’s life and mental health? (2023).
  • Dialysotherapy effect on the quality of life for renal patients (2023).
  • Surgical site infections – an updated review of guidelines (2023).
  • Holistic care, physical activity and healthy lifestyle in PMS patients (2023).

Research Impact

The published studies contribute to healthcare education and clinical awareness by synthesizing current evidence and discussing practical implications for patient care. Topics such as chronic disease management, infection prevention, and rare disease recognition are relevant to clinicians, healthcare educators, and medical researchers. The diversity of subjects represented in her work reflects a commitment to supporting informed healthcare practice.[5]

Award Suitability

Aleksandra Kułakowska’s scholarly activities align with the objectives of the Global Innovation Technologist Awards by demonstrating engagement with healthcare innovation, medical knowledge dissemination, and interdisciplinary research. Her publication record highlights contributions to clinically relevant topics that support evidence-based practice and ongoing scientific dialogue within medicine and health sciences.[6]

Conclusion

Aleksandra Kułakowska has contributed to a range of healthcare-related subjects through peer-reviewed publications addressing patient outcomes, clinical management, and public health concerns. Her academic portfolio reflects sustained engagement with contemporary medical issues and supports the advancement of healthcare knowledge through scholarly communication.

References

  1. ORCID. (n.d.). Aleksandra Kułakowska ORCID record.
    https://orcid.org/0000-0001-5466-7167
  2. Oxford Medical Case Reports. (2025). Schnitzler syndrome – a rare cause of chronic urticaria. Case report.
    DOI: https://doi.org/10.1093/omcr/omaf118
  3. Journal of Education, Health and Sport. (2023). What impact does dialysis have on the patient’s life and mental health?
    DOI: https://doi.org/10.12775/JEHS.2023.39.01.001
  4. Journal of Education, Health and Sport. (2023). Dialysotherapy effect on the quality of life for renal patients.
    DOI: https://doi.org/10.12775/JEHS.2023.28.01.006
  5. Journal of Education, Health and Sport. (2023). Surgical site infections – an updated review of guidelines in the light of new scientific data.
    DOI: https://doi.org/10.12775/JEHS.2023.28.01.002
  6. Journal of Education, Health and Sport. (2023). Concise compilation of the most clinically relevant current knowledge on Brugada Syndrome.
    DOI: https://doi.org/10.12775/JEHS.2023.25.01.001

Mutinda Cleophas Kyama | Medicine and Health Sciences | Research Excellence Award

Published on by Innovation Technologist

Research Excellence Award

Cleophas Mutinda Kyama
Jomo Kenyatta University of Agriculture and Technology, Kenya
Cleophas Mutinda Kyama
Affiliation Jomo Kenyatta University of Agriculture and Technology
Country Kenya
Scopus ID 57216717397
Documents 65
Citations 2,698
h-index 29
Subject Area Medicine and Health Sciences
Event Global Innovation Technologist Awards
ORCID 0000-0001-6459-1514

Cleophas Mutinda Kyama is a Kenyan biomedical scientist, clinical cytologist, and academic researcher associated with the Jomo Kenyatta University of Agriculture and Technology (JKUAT). His scholarly contributions span cancer biology, molecular diagnostics, parasitology, toxicology, infectious disease detection, and translational biomedical sciences. His publication record demonstrates sustained engagement in interdisciplinary health science research with applications in oncology, infectious diseases, immunology, and molecular medicine.[1] The researcher has received significant scholarly attention through citations and collaborative biomedical investigations, particularly in cervical cancer diagnostics, phytomedicine, CRISPR-based diagnostic technologies, and antivenom development.[2]

Abstract

The Research Excellence Award recognition article documents the scholarly achievements and biomedical research contributions of Cleophas Mutinda Kyama. His scientific portfolio encompasses molecular diagnostics, oncology, pharmacological investigations, parasitology, immunological research, and translational health sciences. Through peer-reviewed publications, collaborative international research, and laboratory-based innovations, Kyama has contributed to the advancement of diagnostic technologies and therapeutic investigations relevant to public health challenges in Africa and globally.[3] The researcher’s work demonstrates integration of computational biology, molecular docking, in vitro experimentation, and nanotechnology-assisted diagnostics, reflecting contemporary interdisciplinary scientific approaches.[4]

Keywords

Biomedical Sciences; Molecular Diagnostics; Cervical Cancer Research; CRISPR-Cas12a; Oncology; Cytology; Antivenom Research; Pharmacology; Translational Medicine; Public Health Research; Cancer Therapeutics; Computational Biology.

Introduction

Biomedical and translational health sciences have increasingly relied upon interdisciplinary approaches integrating molecular biology, computational modeling, immunology, and experimental medicine. Within this scientific landscape, Cleophas Mutinda Kyama has contributed to research efforts addressing infectious diseases, cancer diagnostics, toxicology, and therapeutic screening technologies.[5] His work has emphasized practical healthcare applications, particularly within African biomedical contexts where diagnostic accessibility and disease management remain major public health priorities.

Kyama’s research trajectory demonstrates sustained engagement in clinically relevant investigations involving HPV-associated cervical cancer screening, SARS-CoV-2 detection systems, phytochemical anticancer studies, and venom toxicology. Several of his investigations combine computational methodologies with laboratory validation, contributing to evidence-based biomedical innovation and translational healthcare research.[6]

Research Profile

Cleophas Mutinda Kyama served at Jomo Kenyatta University of Agriculture and Technology as a Biomedical Scientist and Senior Lecturer in Medical Laboratory Sciences. His academic and professional work has focused on laboratory diagnostics, cytology, cancer biology, molecular therapeutics, and pathogen detection technologies.[1]

The researcher’s Scopus profile reports 65 scholarly documents with 2,698 citations and an h-index of 29, reflecting measurable scientific visibility and sustained citation impact across biomedical disciplines.[1] His work has appeared in journals including PLOS ONE, BMC Complementary Medicine and Therapies, Diagnostics, Toxicon: X, Toxins, and the South African Journal of Botany.

  • Research specialization in molecular diagnostics and biomedical laboratory sciences.
  • Interdisciplinary research combining computational biology and experimental medicine.
  • Published investigations involving oncology, toxicology, parasitology, and virology.
  • Contributions to public health-oriented biomedical innovation.

Research Contributions

Among Kyama’s notable scientific contributions are investigations into cervical cancer therapeutics and molecular screening technologies. His 2025 study in PLOS ONE explored the molecular mechanisms of Solanecio mannii aqueous root extracts against cervical cancer using computational and experimental validation methodologies.[2]

Additional research explored network pharmacology and molecular docking strategies for prostate cancer treatment investigations using Aspilia pluriseta. These studies integrated in vitro analysis with computational biology techniques to evaluate antiproliferative activity and potential therapeutic mechanisms.[3]

Kyama also contributed to advanced infectious disease diagnostics through CRISPR-Cas12a and hybridization chain reaction methodologies for SARS-CoV-2 detection. This work reflected the growing importance of rapid molecular diagnostic systems during global public health emergencies.[4]

In toxicological and immunological sciences, his studies investigated venom lethality, monoclonal antibody development, and antivenom efficacy involving Naja ashei toxins. These investigations contributed to understanding envenomation management and toxin-neutralizing biomedical strategies.[7]

Publications

Selected publications associated with Cleophas Mutinda Kyama include peer-reviewed journal articles, preprints, and translational biomedical studies relevant to oncology, diagnostics, toxicology, and parasitology.

  1. Computational investigation and experimental validation of the molecular mechanism of Solanecio mannii aqueous roots extract against cervical cancer. PLOS ONE (2025).
  2. Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer. BMC Complementary Medicine and Therapies (2024).
  3. Application of Hybridization Chain Reaction/CRISPR-Cas12a for the Detection of SARS-CoV-2 Infection. Diagnostics (2023).
  4. Evaluation of lethality and cytotoxic effects induced by Naja ashei venom and efficacy of selected antivenoms in Kenya. Toxicon: X (2022).
  5. Development and Characterization of Anti-Naja ashei Three-Finger Toxins-Specific Monoclonal Antibodies. Toxins (2022).

Research Impact

The scientific impact of Cleophas Mutinda Kyama’s work is reflected through citation metrics, interdisciplinary collaborations, and practical biomedical applications. His investigations into molecular diagnostics and therapeutic evaluation contribute to contemporary discussions surrounding affordable healthcare technologies, precision diagnostics, and evidence-based medicinal research.[4]

Research involving CRISPR-based diagnostics and nanoparticle-assisted detection systems demonstrates alignment with emerging biomedical technologies that support rapid pathogen identification and translational healthcare innovation.[8] Similarly, his toxicological and antivenom studies address healthcare concerns related to snakebite management in endemic regions.

The integration of phytomedicine, computational molecular analysis, and laboratory validation techniques further reflects a multidisciplinary scientific framework capable of supporting future biomedical innovation and collaborative translational research initiatives.[3]

Award Suitability

The scholarly profile of Cleophas Mutinda Kyama demonstrates characteristics associated with international academic recognition and research excellence awards. His documented publication history, citation impact, interdisciplinary biomedical investigations, and sustained engagement in translational health sciences collectively support recognition within the framework of the Global Innovation Technologist Awards.[1]

  • Demonstrated publication productivity in indexed scientific journals.
  • Strong citation impact and measurable academic influence.
  • Contributions to molecular diagnostics and translational medicine.
  • Interdisciplinary biomedical innovation relevant to public health.
  • Research engagement involving computational and experimental methodologies.

Conclusion

Cleophas Mutinda Kyama has established a research profile characterized by interdisciplinary biomedical inquiry, molecular diagnostic innovation, and translational scientific investigations addressing major health challenges. His academic contributions in oncology, toxicology, molecular biology, and infectious disease diagnostics demonstrate sustained scholarly engagement and measurable scientific impact.[5] Through collaborative biomedical research and publication activity, his work contributes to evolving scientific understanding within medicine and health sciences while supporting broader healthcare research objectives relevant to emerging global health priorities.

References

  1. Elsevier. (n.d.). Scopus author details: Cleophas Mutinda Kyama, Author ID 57216717397. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57216717397
  2. Kyama, C. M. et al. (2025). Computational investigation and experimental validation of the molecular mechanism of Solanecio mannii aqueous roots extract against cervical cancer. PLOS ONE.
    https://doi.org/10.1371/journal.pone.0323680
  3. Kyama, C. M. et al. (2024). Network pharmacology, molecular docking, and in vitro study on Aspilia pluriseta against prostate cancer. BMC Complementary Medicine and Therapies.
    https://doi.org/10.1186/s12906-024-04642-8
  4. Kyama, C. M. et al. (2023). Application of Hybridization Chain Reaction/CRISPR-Cas12a for the Detection of SARS-CoV-2 Infection. Diagnostics.
    https://doi.org/10.3390/diagnostics13091644
  5. Jomo Kenyatta University of Agriculture and Technology. (n.d.). Medical Laboratory Sciences and Biomedical Research Activities.
  6. Kyama, C. M. et al. (2022). Expression of the Fab enzymes from Plasmodium falciparum after exposure to Artemisia afra plant extracts. Journal of Parasitic Diseases.
    https://doi.org/10.1007/s12639-022-01537-8
  7. Kyama, C. M. et al. (2022). Development and Characterization of Anti-Naja ashei Three-Finger Toxins-Specific Monoclonal Antibodies. Toxins.
    https://doi.org/10.3390/toxins14040285
  8. Kyama, C. M. et al. (2020). Development of HPV 16/18 E6 oncoprotein paper-based nanokit for enhanced cervical cancer screening.
    https://doi.org/10.1101/2020.04.29.20084459

Tambwe Willy Muzumbukilwa | Pharmacology | Research Excellence Award

Published on by Innovation Technologist

Assoc. Prof. Dr. Tambwe Willy Muzumbukilwa | Pharmacology | Research Excellence Award

Lecturer and Medical Doctor | University of Kwazulu-Natal | South Africa

Assoc. Prof. Dr. Tambwe Willy Muzumbukilwa is a pharmacologist and medical researcher specializing in healthcare quality management, with a strong focus on HIV/AIDS clinical care and treatment outcomes. His research advances the development and validation of quality indicators to improve clinical performance and health system effectiveness in resource-limited settings. He has published extensively in peer-reviewed international journals on HIV care quality, treatment outcomes, and health systems evaluation across Southern and Central Africa. His work bridges clinical medicine, public health, and pharmacology to strengthen evidence-based healthcare delivery for vulnerable populations.

Citation Metrics (Scopus)

50

40

30

20

10

0

Citations 44

Documents 10

h-index 4

                    🟦 Citations      🟥 Documents      🟩 h-index


View Scopus Profile

Featured Publications

Clinical and epidemiological research contributions in HIV care, COVID-19 outcomes, and public health systems in sub-Saharan Africa

– Scopus-indexed publications

Research on infectious disease outcomes, hospital admission pathways, and health-system preparedness

– Ongoing & peer-reviewed studies

Yi Gou | Medicinal Chemistry | Best Researcher Award

Published on by Innovation Technologist

Mr. Yi Gou | Medicinal Chemistry | Best Researcher Award

Associate Researcher at Guilin Medical University, China

Yi Gou is a distinguished researcher in anticancer drug chemistry with a strong academic background and a track record of innovation. He has authored over 40 SCI papers, with a significant number of first-author publications. His groundbreaking research has led to multiple patents and contributions to international scientific literature. Yi has also served as a guest editor for renowned journals such as Frontiers in Pharmacology and Drug Development Research. His expertise and research are recognized globally, contributing to advancements in cancer therapy.

Publication Profile : 

Scopus

Educational Background 🎓

Yi Gou earned a Ph.D. in Inorganic Chemistry in 2016. During his doctoral research, he specialized in the field of anticancer drug chemistry, laying the foundation for his subsequent work. His extensive education and training have provided him with a solid understanding of both inorganic chemistry and medicinal chemistry, particularly in designing and synthesizing anticancer small molecule agents. This expertise has guided his research in the development of novel drug candidates, and his academic achievements include numerous publications in high-impact journals.

Professional Experience 💼

Yi Gou is currently serving as an Associate Researcher at Guilin Medical University, where he continues his pioneering research on anticancer drug chemistry. His professional career includes both independent research projects and collaborative work, notably contributing to the National Natural Science Foundation of China (NSFC) projects. He has led one completed NSFC project (Project No. 22007023) and is actively conducting another (Project No. 22267004). In addition to his research, Yi Gou has also been recognized for his editorial contributions, serving as a guest editor for journals such as Frontiers in Pharmacology and Drug Development Research. Over the years, his work has resulted in numerous publications, patents, and positive evaluations in the international research community.

Research Interests 🔬

Yi’s primary research focus is on the design and synthesis of small molecule anticancer agents, particularly those involving metal-based complexes. His work merges the fields of inorganic chemistry and medicinal chemistry, with a focus on developing novel therapeutics to combat cancer. Yi has received significant funding for his research, completing one National Natural Science Foundation of China project (Project No. 22007023) and currently leading another (Project No. 22267004). His work has led to eight Chinese invention patents and multiple collaborations, including research on metal-antitumor complexes based on traditional Chinese medicine components.

Key Achievements

🔬 Over 40 published SCI papers, with an h-index of 24
📜 8 Chinese invention patents granted, 6 in the process of application
🔗 Collaborations with leading researchers and national projects
🌍 Recognized as a guest editor for prominent journals
🎓 Member of the Chinese Chemical Society

Publications 📚

  • Li, A., Pan, W., Zhang, Z., Zhang, Y., & Ma, L. (2025). Hydrazone copper(II) complexes suppressed lung adenocarcinoma by activating multiple anticancer pathways. Bioorganic Chemistry, 154, 107994.
  • Li, A., Huang, K., Pan, W., Ma, L., & Gou, Y. (2024). Thiosemicarbazone mixed-valence Cu(I/II) complex against lung adenocarcinoma cells through multiple pathways involving cuproptosis. Journal of Medicinal Chemistry, 67(11), 9091–9103.

  • Wu, Y., Wu, D., Lan, J., Xu, Y., & Gou, Y. (2024). Assessment of mononuclear/dinuclear copper acylhydrazone complexes for lung cancer treatment. Bioorganic Chemistry, 144, 107122.

  • Deng, J., Wu, Y., Li, A., Yang, F., & Gou, Y. (2023). Dithiocarbazate-Zn(II) complexes for photodynamic therapy and chemotherapy against lung cancer. Inorganic Chemistry Frontiers, 10(22), 6526–6536.

  • Wu, Y., Hou, L., Lan, J., Liu, W., & Gou, Y. (2023). Mixed-ligand copper(II) hydrazone complexes: Synthesis, structure, and anti-lung cancer properties. Journal of Molecular Structure, 1279, 134986.
  • Gou, Y., Liu, L., & Liang, H. (2022). Editorial: The developments of metal-based agents against lung cancer. Frontiers in Pharmacology, 13, 1101890.
  • Chen, M., Chen, X., Huang, G., Gou, Y., & Deng, J. (2022). Synthesis, anti-tumour activity, and mechanism of benzoyl hydrazine Schiff base-copper complexes. Journal of Molecular Structure, 1268, 133730.
  • Deng, J., Peng, C., Hou, L., Huang, G., & Gou, Y. (2022). Dithiocarbazate-copper complex loaded thermosensitive hydrogel for lung cancer therapy via tumor in situ sustained-release. Inorganic Chemistry Frontiers, 9(23), 6190–6201.
  • Guo, J., Li, A., Guo, R., Jin, J., & Huang, G. (2022). C1orf74 positively regulates the EGFR/AKT/mTORC1 signaling in lung adenocarcinoma cells. PeerJ, 10, e13908.
  • Gou, Y., Jia, X., Hou, L. X., Jiang, H. W., & Yang, F. (2022). Dithiocarbazate-Fe(III), -Co(III), -Ni(II), and -Zn(II) complexes: Design, synthesis, structure, and anticancer evaluation. Journal of Medicinal Chemistry, 65(9), 6677–6689.